Detail akcie Neumora Rg online

Business Summary: Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The Company's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD).
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Neumora Therapeutics Inc revenues was not reported. Net loss decreased 4% to $177.5M. Lower net loss reflects Biotechnology and medical research segment loss decrease of 9% to $182.7M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.16 to -$1.10.